- Home
- KWR vs ARQT Comparison
KWR vs ARQT Comparison
Compare KWR & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KWR | ARQT |
|---|---|---|
| Founded | 1918 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.2B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KWR | ARQT |
|---|---|---|
| Price | $150.16 | $32.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $193.14 | $39.13 |
| AVG Volume (30 Days) | 101.6K | ★ 2.2M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 4.40 | 0.03 |
| Revenue | ★ $1,888,634,000.00 | $376,072,000.00 |
| Revenue This Year | $7.73 | $43.21 |
| Revenue Next Year | $4.53 | $29.18 |
| P/E Ratio | ★ $58.88 | $1,062.00 |
| Revenue Growth | 2.66 | ★ 91.34 |
| 52 Week Low | $112.18 | $19.30 |
| 52 Week High | $183.01 | $33.30 |
Technical Indicators
Market Signals| Indicator | KWR | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 39.63 | 65.90 |
| Support Level | $146.56 | $22.93 |
| Resistance Level | $155.88 | $33.30 |
| Average True Range (ATR) | 4.48 | 1.39 |
| MACD | -0.46 | 0.19 |
| Stochastic Oscillator | 6.33 | 84.55 |
Price Performance
Historical ComparisonAbout KWR Quaker Houghton
Quaker Houghton manufactures and sells a variety of industrial process fluids. The company's product portfolio includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids, and surface treatment chemicals. The company's geographic segments include the Americas, EMEA, and Asia/Pacific. The majority of the company's revenue is earned from the Americas.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.